Orthofix Med Inc Stock Price, News & Analysis

Orthofix Medical Inc. (NASDAQ:OFIX) has announced its plans to report financial results for the fourth quarter and full year 2020 on February 26, 2021, before market open. CEO Jon Serbousek and CFO Doug Rice will discuss the results during a conference call at 8:30 a.m. ET that day. Interested participants can join the call by dialing specific numbers or access a webcast through the company's investor relations website. Orthofix is focused on innovative medical device solutions, distributing products in over 70 countries.

Orthofix Medical Inc. (NASDAQ:OFIX) announced the full market launch of its FITBONE® intramedullary lengthening system in the U.S. and Europe for femur and tibia deformity corrections. The system, which is fully implantable, has been used in over 3,500 cases across 15 countries. It gained U.S. FDA 510(k) clearance and CE Mark approval in Europe. This expansion aims to improve treatment options for surgeons and patients. Orthofix offers a comprehensive portfolio of fixation solutions, enhancing its market presence in orthopedic care.

Orthofix Medical (NASDAQ:OFIX) published two-year data from its U.S. IDE study of the M6-C™ artificial cervical disc, demonstrating that the device is safe and effective for treating cervical disc degeneration. The study showed an overall success rate of 86.8% for M6-C patients compared to 79.3% for anterior cervical discectomy and fusion (ACDF) patients. At 24 months, M6-C patients reported significant reductions in pain and medication use, with a 91.2% improvement in neck pain. Orthofix aims to enhance patient outcomes with this innovative technology, emphasizing its commitment to quality-driven medical solutions.

Orthofix Medical Inc. (NASDAQ:OFIX) reported preliminary fourth quarter 2020 net sales of approximately $118 million, down 3% year-over-year. Full year net sales totaled about $407 million, a 12% decrease from 2019. Sequentially, Q4 sales rose 6% from Q3 2020, driven mainly by the Spinal Implants segment. Despite COVID-19 challenges, the company noted stable sales in Bone Growth Therapies and growth in Spinal Implants due to the M6-C™ artificial cervical disc. Cash reserves improved to approximately $96-97 million compared to $70 million in 2019.

Orthofix Medical announced participation in two investor conferences on January 14, 2021. President Jon Serbousek and CFO Doug Rice will present at the J.P. Morgan Healthcare Conference at 2:00pm ET and the ICR Westwicke Conference at 4:00pm ET. Both presentations will be live-streamed and accessible on the company's investor relations website. Orthofix, headquartered in Lewisville, Texas, focuses on innovative medical devices and biologics for spine and extremities, distributing products in over 70 countries.

Orthofix Medical Inc. (NASDAQ: OFIX) announced that President and CEO Jon Serbousek will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 10:40 a.m. ET. The event will be virtual, including one-on-one meetings surrounding the chat. A live audio webcast will be accessible on the company's website.

Orthofix is a global medical device and biologics company focused on spine and extremities, distributing products in over 70 countries and partnering with healthcare professionals to improve patient lives.

Orthofix Medical Inc. (NASDAQ: OFIX) has announced its plans to release financial results for Q3 2020 on November 5, 2020, before market open. CEO Jon Serbousek and CFO Doug Rice will host a conference call at 8:30 a.m. ET that same day to discuss the results. Interested parties can join the call by dialing the provided numbers, and a replay will be available for three weeks. Orthofix focuses on musculoskeletal products and therapies, distributing its offerings in over 70 countries.

Orthofix Medical Inc (NASDAQ:OFIX) announced its participation in the virtual North American Spine Society (NASS) 2020 meeting from October 6-9, showcasing multiple clinical abstracts. The company emphasized its focus on building clinical evidence for its technologies, including the M6-C artificial cervical disc and Trinity ELITE Allograft. Key presentations highlighted clinical results and ongoing studies related to spine innovations, showcasing the potential benefits of their products in surgery and patient outcomes.

Orthofix Medical (NASDAQ:OFIX) has received FDA 510(k) clearance for its FIREBIRD SI Fusion System, which features innovative nanotechnology. This system, designed for stabilizing the sacroiliac joint during fusion, utilizes a 3D-printed titanium bone screw enhanced with a unique nano-surface. It aims to facilitate better recovery through a minimally invasive procedure, accommodating various patient anatomies. This announcement is part of Orthofix's strategy to present its advancements at the upcoming North American Spine Society annual meeting.